At Extreme Investor Network, we provide unique insights into the latest economic trends and news affecting global markets. In our latest blog post, we dive into the alarming rise of Creutzfeldt-Jakob disease (CJD) and its potential link to the mRNA vaccine.
CJD, a rare brain disorder that leads to dementia, has seen a sudden uptick in cases in recent years. Prions, which are known to break down proteins, have been linked to this debilitating disease. Could there be a connection between the rise in CJD cases and the mRNA vaccine?
According to reports, there have been 42 confirmed cases of CJD following COVID vaccination, as reported to the Vaccine Adverse Reporting System (VAERS). Despite these alarming numbers, there seems to be reluctance to associate these cases with the experimental jab.
The National Institutes of Health (NIH) recently made headlines for admitting the use of taxpayer funds to study gain-of-function research in Wuhan. This controversial research, which involves enhancing the transmissibility and pathogenicity of viruses, has been at the center of debates surrounding the origins of the COVID-19 pandemic.
While NIH Director Lawrence Tabak finally acknowledged their involvement in gain-of-function research, claiming it posed no threat, questions remain about the ethics and oversight of such studies. The continued funding of the Wuhan Institute of Virology by the US Department of Health and Human Services raises further concerns about accountability and transparency.
Amidst the controversy, figures like Senator Rand Paul have been vocal in holding individuals like Anthony Fauci accountable for their roles in the pandemic response. As questions linger about the origins of the virus and the handling of the crisis, it is essential to demand transparency and accountability from those in positions of power.
At Extreme Investor Network, we strive to provide valuable insights and analysis on economic events that impact investors and policymakers. Stay tuned for more updates on the latest developments in the world of economics and finance.